Rheumatology Practice Valuation: How Is It Valued?
Rheumatology practice valuation is rarely as simple as looking at total revenue. A practice with a busy infusion suite may report large collections, yet much of that money passes through to drug acquisition costs. Buyers, sellers and lenders all need to understand what the practice truly earns and how durable those earnings are.
This article explains the factors that typically drive value in a rheumatology practice and how they affect financing. Valuation methods, ownership rules and payer rules vary, and nothing here is legal, tax, billing or compliance advice. A formal valuation should be prepared by qualified professionals.
Start With Cash Flow, Not Collections
Most practice valuations center on normalized cash flow, often described as earnings available to an owner after paying a market salary to the physician who will provide care. Gross collections can be misleading in rheumatology because infused biologics carry high costs.
To normalize earnings, valuers and buyers often:
- Separate professional revenue from drug revenue and drug cost
- Replace the owner’s actual compensation with a market physician salary
- Review proposed add-backs and remove items that will not continue
- Adjust for unusual years, such as a staffing gap or a one-time payer settlement
- Consider rent at market rates if the owner also owns the building
The result is a clearer view of what a new owner could expect to earn.
How Infusion Revenue Affects Rheumatology Practice Valuation
Infusion services can add meaningful value, but buyers usually look at the margin rather than the gross. Key questions include which drugs drive the margin, how payment rates have moved over time and how dependent the program is on a few products.
Drug margins can shift as payers change policies, as biosimilars enter the market and as federal drug pricing rules evolve. A program that has already adapted to biosimilars and diversified across therapies may be viewed as more durable. Our article on rheumatology drug reimbursement risk covers how lenders think about this exposure.
Payer Mix and Patient Base
Rheumatology patients often have chronic conditions and return for ongoing care, which can support stable visit volume. Value is influenced by the mix of Medicare, Medicaid and commercial insurers, the strength of payer contracts and how promptly claims are paid.
Buyers will also look at the size of the active patient panel, how new patients arrive and whether referrals come from a broad group of primary care physicians or a few sources. Concentration in one referral source or one payer tends to increase perceived risk.
Physician Dependence and the Care Team
A solo practice where the owner sees nearly every patient is generally more exposed to a change in ownership than a group with several physicians and advanced practice providers. Valuers often consider:
- The share of visits provided by the selling physician
- Whether other providers have established panels
- Infusion nurse and staff tenure
- How long the seller will stay to introduce the buyer
A documented transition plan can help support value because it reduces the chance that patients leave after closing. Joint visits, letters to patients and introductions to referring physicians are practical steps that buyers and sellers often agree on in advance.
Ancillary Services and Equipment
Musculoskeletal ultrasound and bone density imaging can add revenue, but they also come with equipment age, maintenance and replacement needs. Buyers typically review equipment lists, service records, existing leases and any outstanding equipment loans that will need to be paid off or assumed.
Real Estate and Facilities
When the seller owns the building, the real estate is often valued separately from the practice. The practice valuation then reflects a market rent, and the building is priced on its own. Separating the two makes it easier for buyers and lenders to see the true operating cash flow. It also lets a buyer decide whether to purchase the building now, lease it from the seller or revisit ownership later, and each choice can be financed differently.
Working Capital and Drug Inventory
Drug inventory and accounts receivable can be large in a rheumatology practice. Purchase agreements often address how inventory will be counted and paid for at closing, and whether receivables stay with the seller or transfer to the buyer. Those terms can significantly change what a buyer pays at closing, so they should be negotiated with counsel and accountants.
How Lenders Use Rheumatology Practice Valuation
Lenders generally want to see that the purchase price is supported by cash flow that can cover debt payments with a margin of safety. They may review the valuation, historical tax returns, the buyer’s experience and liquidity. Conventional practice loans and SBA-backed loans each follow their own underwriting standards. Eligibility and terms depend on the business, the buyer, use of proceeds, program rules and lender review, every loan is subject to approval, and nothing here is a commitment to lend.
Buyers can learn more about the process in our guide to buying a rheumatology practice.
Tips for Sellers
Sellers who want a stronger result often prepare well before going to market. Clean financial statements, documented add-backs, a clear breakdown of infusion margins and a plan for transitioning patients can make a practice easier to evaluate and finance. Our article on how to sell a rheumatology practice covers preparation in more detail, and our advisory and consulting services can help owners think through succession.
Final Thoughts
Rheumatology practice valuation depends on more than revenue. Normalized cash flow, infusion margins, payer mix, physician dependence and the handling of inventory and real estate all shape what a practice is worth and how a purchase can be financed.
US Medical Funding helps rheumatologists finance practice acquisitions based on realistic cash flow. Learn more about our rheumatology practice acquisition financing.



